دورية أكاديمية
Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection.
| العنوان: | Persistent differences in the immunogenicity of the two COVID-19 primary vaccines series, modulated by booster mRNA vaccination and breakthrough infection. |
|---|---|
| المؤلفون: | Lee KY; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Song KH; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea., Lee KH; Division of Infectious Diseases, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Baek JY; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Asia Pacific Foundation for Infectious Diseases (APFID), Seoul, Republic of Korea., Kim ES; Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea., Song YG; Division of Infectious Diseases, Department of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Kim YC; Division of Infectious Diseases, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea., Park YS; Division of Infectious Diseases, Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Republic of Korea., Ahn JY; Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Choi JY; Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea., Choi WS; Division of Infectious Diseases, Department of Internal Medicine, Korea University Ansan Hospital, Korea University College of Medicine, Ansan, Republic of Korea., Bae S; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Kim SW; Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Republic of Korea., Kwon KT; Division of Infectious Diseases, Department of Internal Medicine, Kyungpook National University Chilgok Hospital, School of Medicine, Kyungpook National University, Daegu, Republic of Korea., Kang ES; Department of Laboratory Medicine and Genetics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Peck KR; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea., Kim SH; Department of Infectious Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Electronic address: shkimmd@amc.seoul.kr., Jeong HW; Department of Internal Medicine, Chungbuk National University College of Medicine, Cheongju, Republic of Korea. Electronic address: hwjeong@chungbuk.ac.kr., Ko JH; Division of Infectious Diseases, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. Electronic address: jaehoon.ko@samsung.com. |
| المصدر: | Vaccine [Vaccine] 2024 Jul 25; Vol. 42 (19), pp. 3953-3960. Date of Electronic Publication: 2024 May 09. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Country of Publication: Netherlands NLM ID: 8406899 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-2518 (Electronic) Linking ISSN: 0264410X NLM ISO Abbreviation: Vaccine Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Amsterdam, The Netherlands : Elsevier Science Original Publication: [Guildford, Surrey, UK] : Butterworths, [c1983- |
| مواضيع طبية MeSH: | Immunization, Secondary* , BNT162 Vaccine*/immunology , BNT162 Vaccine*/administration & dosage , SARS-CoV-2*/immunology , COVID-19*/prevention & control , COVID-19*/immunology , Antibodies, Viral*/blood , Antibodies, Viral*/immunology , COVID-19 Vaccines*/immunology , COVID-19 Vaccines*/administration & dosage, Humans ; Male ; Female ; Prospective Studies ; Adult ; Middle Aged ; Immunogenicity, Vaccine ; Spike Glycoprotein, Coronavirus/immunology ; Cytokines/blood ; Republic of Korea ; ChAdOx1 nCoV-19/immunology ; Health Personnel ; Vaccination/methods ; Breakthrough Infections |
| مستخلص: | Introduction: The long-term impact of initial immunogenicity induced by different primary COVID-19 vaccine series remains unclear. Methods: A prospective cohort study was conducted at 10 tertiary hospitals in Korea from March 2021 to September 2022. Immunogenicity assessments included anti-spike protein antibody (Sab), SARS-CoV-2-specific interferon-gamma releasing assay (IGRA), and multiplex cytokine assays for spike protein-stimulated plasma. Spike proteins derived from wild-type SARS-CoV-2 and alpha variant (Spike Results: A total of 235 healthcare workers who had received a two-dose primary vaccine series of either ChAdOx1 or BNT162b2, followed by a third booster dose of BNT162b2 (166 in the ChAdOx1/ChAdOx1/BNT162b2 (CCB) group and 69 in the BNT162b2/BNT162b2/BNT162b2 (BBB) group, based on the vaccine series) were included. Following the primary vaccine series, the BBB group exhibited significantly higher increases in Sab levels, IGRA responses, and multiple cytokines (CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, interleukin (IL)-1ra, IFN-γ, IL-2, IL-4, and IL-10) compared to the CCB group (all P < 0.05). One month after the third BNT162b2 booster, the CCB group showed Sab levels comparable to those of the BBB group, and both groups exhibited lower levels after six months without breakthrough infections (BIs). However, among those who experienced BA.1/2 BIs after the third booster, Sab levels increased significantly more in the BBB group than in the CCB group (P < 0.001). IGRA responses to both Spike Conclusion: Differences in immunogenicity induced by the two primary vaccine series persisted, modulated by subsequent booster vaccinations and BIs. Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 Elsevier Ltd. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Breakthrough infection; COVID-19; Cytokine; Interferon-gamma releasing assay; SARS-CoV-2; Vaccine |
| المشرفين على المادة: | 0 (BNT162 Vaccine) 0 (Antibodies, Viral) 0 (COVID-19 Vaccines) 0 (Spike Glycoprotein, Coronavirus) 0 (Cytokines) B5S3K2V0G8 (ChAdOx1 nCoV-19) 0 (spike protein, SARS-CoV-2) |
| SCR Disease Name: | COVID-19 breakthrough infections |
| SCR Organism: | SARS-CoV-2 variants |
| تواريخ الأحداث: | Date Created: 20240510 Date Completed: 20240711 Latest Revision: 20240711 |
| رمز التحديث: | 20240712 |
| DOI: | 10.1016/j.vaccine.2024.05.003 |
| PMID: | 38729909 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1873-2518 |
|---|---|
| DOI: | 10.1016/j.vaccine.2024.05.003 |